Concepedia

Weishi Yuan

WY

Statistics

Publications

11

Citations

8.1K

H-Index

11

Active since

2002

Affiliations

Center for Drug Evaluation and Research(Current)

United States Food and Drug Administration

Center for Biologics Evaluation and Research

Johns Hopkins University

Weishi Yuan is an author at Center for Drug Evaluation and Research specializing in oncology, pharmacology, and medicine.

Publications per year

2002–2022

11

Publications

11

<i>IDH1</i>and<i>IDH2</i>Mutations in Gliomas

Hai Yan, D. Williams Parsons, Genglin Jin et al. · New England Journal of Medicine · 2009 · 5.9K citations · Full text

Medicine, Genetics, Oncology +16

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

Robert Q. Le, Liang Li, Weishi Yuan et al. · The Oncologist · 2018 · 882 citations · Full text

Life Sciences, Immunology, Pharmacology +16

Allelic Variation in Human Gene Expression

Hai Yan, Weishi Yuan, Victor E. Velculescu et al. · Science · 2002 · 628 citations

Life Sciences, Genetics, Molecular Genetics +10

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

Erin Larkins, Gideon M. Blumenthal, Weishi Yuan et al. · The Oncologist · 2017 · 216 citations · Full text

Medicine, Oncology, Pharmacology +16

FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous Transplantation

Michael H. Brave, Ann T. Farrell, Sue Ching Lin et al. · Oncology · 2010 · 143 citations

Medicine, Hematology, Pharmacology +17

1–5 of 11